GMA Holdings, Inc. (PSE:GMAP)

Ligand Pharmaceuticals Income Statement

Financials in millions PHP. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	0.73	0.52	0.16	3.22	9.35	2.02
Other Revenue	3.06	3.03	2.63	1.78	1.74	1.29
Revenue	3.8	3.55	2.79	5	11.09	3.31
Revenue Growth (YoY)	32.52%	27.24%	-44.27%	-54.89%	234.95%	24.62%
Gross Profit	3.8	3.55	2.79	5	11.09	3.31
Selling, General & Admin	0.59	0.49	0.9	0.49	0.54	0.52
Other Operating Expenses	0.05	0.05	0.04	0.07	0.04	0.09
Operating Expenses	0.63	0.53	0.93	0.55	0.57	0.61
Operating Income	3.17	3.01	1.85	4.45	10.51	2.7
Other Non Operating Income (Expenses)	-0.31	-0.33	-0.44	-0.64	-0.41	-0.4
Pretax Income	2.85	2.68	1.42	3.81	10.1	2.31
Income Tax Expense	0.48	0.45	0.22	0.5	2.18	0.27
Net Income	2.37	2.24	1.2	3.3	7.93	2.03
Net Income to Common	2.37	2.24	1.2	3.3	7.93	2.03
Net Income Growth	78.87%	86.96%	-63.81%	-58.32%	289.68%	58.07%
Dividend Per Share	0.500	0.500	0.600	1.100	1.450	1.350
Dividend Growth	-16.67%	-16.67%	-45.45%	-24.14%	7.41%	350.00%
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	83.40%	85.00%	66.52%	88.92%	94.83%	81.70%
Profit Margin	62.52%	63.02%	42.89%	66.06%	71.49%	61.45%
EBIT	3.17	3.01	1.85	4.45	10.51	2.7
EBIT Margin	83.40%	85.00%	66.52%	88.92%	94.83%	81.70%
Effective Tax Rate	16.81%	16.64%	15.74%	13.20%	21.55%	11.85%
Revenue as Reported	-	-	-	-	11.09	3.31

Updated Nov 13, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.